<DOC>
	<DOCNO>NCT02706951</DOCNO>
	<brief_summary>This randomize , double-blind study compare ABT-494 monotherapy Methotrexate ( MTX ) monotherapy subject moderately severely active rheumatoid arthritis inadequate response methotrexate treatment .</brief_summary>
	<brief_title>A Study Comparing ABT-494 Monotherapy Methotrexate ( MTX ) Monotherapy Subjects With Rheumatoid Arthritis ( RA ) Who Have Inadequate Response MTX ( SELECT-MONOTHERAPY )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis RA &gt; = 3 month . Subjects must oral parenteral MTX therapy &gt; = 3 month stable dose &gt; = 4 week prior first dose study drug . Must discontinue conventional synthetic diseasemodifying antirheumatic drug ( csDMARDs ) ( MTX ) &gt; = 4 week prior first dose study drug . Meets follow minimum disease activity criterion : &gt; = 6 swollen joint ( base 66 joint count ) &gt; = 6 tender joint ( base 68 joint count ) Screening Baseline Visits . Prior exposure Janus kinase ( JAK ) inhibitor ( include limit tofacitinib , baricitinib , filgotinib ) . Prior exposure biological diseasemodifying antirheumatic drug ( bDMARDs ) . Current diagnosis inflammatory joint disease RA . Current diagnosis secondary Sjogren 's Syndrome permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Musculoskeletal Disease</keyword>
	<keyword>anti-inflammatory agent</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Joint Disease</keyword>
	<keyword>antirheumatic agent</keyword>
</DOC>